How quickly will Wegovy work — what the evidence actually shows

What the STEP 1 trial found, and what it means for weeks one to eight

The clearest starting point is the trial evidence. In the STEP 1 study published in the New England Journal of Medicine, 1,961 adults with obesity or overweight plus at least one weight-related condition took semaglutide 2.4mg weekly alongside lifestyle changes for 68 weeks. The average weight reduction was around 15%. That figure is an average across a large, varied group, some participants lost considerably more, others less.

More useful for understanding timing is what happened early on. The dose during the first four weeks is 0.25mg, which is a tolerability stage: the drug is settling into your system, and your prescriber will move you up in steps. Most participants in the trial reported reduced hunger relatively early, often before the scale had shifted much. That disconnect is common and worth knowing about in advance, you may feel less interested in food before you see any change in weight.

By weeks four to eight, as the dose increases, the appetite-suppressing effect tends to become more noticeable. If you want a fuller picture of how quickly Wegovy works for weight loss, including what to realistically expect as the dose steps up, that page goes into the early evidence in more detail. Consistency with doses and lifestyle modifications during this phase lays the groundwork for what comes later. If you want a fuller picture of the early weeks, our page on how long Wegovy takes to work maps the titration schedule in more detail.

Months two to six, the period where most progress accumulates

Once the maintenance dose of 2.4mg is reached (typically around month five of titration), weight loss tends to accelerate. The STEP 1 data show the steepest reduction in body weight occurring broadly between weeks 8 and 40, a long, sustained period rather than a quick burst. This is worth sitting with, because people sometimes expect the biggest changes to arrive in the first few weeks and worry when they don't.

Side effects are worth mentioning here, because they can affect how quickly someone reaches the maintenance dose. Nausea, loose stools, indigestion and reduced appetite for specific foods are the most commonly reported. These are usually most noticeable after starting or after a dose step-up, and they tend to settle over days to a couple of weeks for most people. The NHS medicines page for semaglutide covers the side-effect profile in full and is the right place to read it carefully rather than relying on anyone's brief summary.

People who stay on treatment through the titration phase and manage side effects with small practical changes (smaller meals, more frequent eating, staying hydrated) tend to do better in this accumulation window. This is also the window that feeds into the six-month clinical review that NICE guidance references.

Six months and beyond, the clinical checkpoint and longer-term picture

NICE's recommendation for semaglutide (Wegovy) includes a specific review point: if someone has not achieved at least 5% weight loss after six months on the maintenance dose, continuing treatment should be discussed with a clinician. That is not a failure threshold, it is a safety net built into the clinical framework to make sure the medicine is actually doing what it should for each individual person.

Beyond six months, weight loss typically slows and then plateaus at a level the body can sustain. In STEP 1, average weight loss at 68 weeks was around 15%, with many participants losing significantly more. Our page covering how quickly Wegovy works looks at these longer timelines in more depth, including what the data say about the point at which most people reach their plateau. For a broader look at how Wegovy compares to other options, our Wegovy treatment overview covers the full licensed picture.

Longer-term use requires ongoing clinical review. The NICE recommendation for Wegovy is for use within a specialist weight management pathway for up to two years; your prescriber will factor this into any repeat assessment. At nume, every repeat order is clinically reviewed (there are no auto-renewals) so the question of how treatment is working for you is revisited before each new supply.

Factors that affect pace, and why individual results vary

Clinical trial averages describe a population, not a person. Several factors influence how quickly Wegovy works for any given individual: starting weight and body composition, how well side effects are managed during titration, diet and activity levels alongside treatment, other medicines, and metabolic factors that no simple consultation question can fully capture.

The cost of treatment is something people reasonably want to weigh against expected timelines, our Wegovy cost page sets out what a realistic private prescription includes and what the market looks like. Separately, questions about rate of loss on semaglutide more broadly are covered in detail at how quickly you'll lose weight on semaglutide, which is worth reading alongside this page.

One practical note: when your treatment arrives with DPD in plain, unbranded packaging, the pen inside is a pre-filled KwikPen containing four weekly doses. Keeping it refrigerated from arrival, and reading the Patient Information Leaflet before the first injection, is the starting point. The pace from there is a clinical matter, which is exactly why a prescriber reviews your case before every supply rather than just processing a repeat automatically. If you'd like to talk through where you are in treatment or whether Wegovy is the right route for you, speaking to our prescribers is the first step.